Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supplement Risk Limits Set “Substantially” Below Drugs By DSHEA, FDA Told

This article was originally published in The Tan Sheet

Executive Summary

In the context of the Dietary Supplement Health & Education Act, the type of risk from dietary supplements that should be considered "significant or unreasonable" may be "substantially less serious than the types of risk that would be considered significant or unreasonable for drugs," according to April 4 congressional comments to FDA

You may also be interested in...



Ephedra Safety Risk Evidence Sufficient For Market Ban – Rep. Waxman

There is currently enough evidence of risk to remove ephedra from the market, Rep. Henry Waxman (D-Calif.) maintained at the Food & Drug Law Institute's Annual Educational Conference in Washington, D.C. April 1

DSHEA Legislative Reform Effort Likely In 108th Congress Behind Sen. Durbin

Legislation to amend the Dietary Supplement Health & Education Act is a long-term goal of Sen. Richard Durbin (D-Ill.), according to his staff

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel